v3.19.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating expenses        
Research and development $ 1,986,000 $ 524,000 $ 5,212,000 $ 1,793,000
General and administrative 1,037,000 810,000 3,354,000 2,102,000
Grant reimbursements (716,000) (1,914,000)
Gain on settlement (635,000) (635,000)
Total operating expenses, net 1,672,000 1,334,000 6,017,000 3,895,000
Loss from operations (1,672,000) (1,334,000) (6,017,000) (3,895,000)
Interest expense, net (223,000) (322,000) (2,864,000) (767,000)
Other income (expense), net 151,000 (94,000) 211,000
Loss from continuing operations (1,895,000) (1,505,000) (8,975,000) (4,451,000)
Loss from discontinued operations (58,000)
Net loss $ (1,895,000) $ (1,505,000) $ (9,033,000) $ (4,451,000)
Net loss per basic and diluted share:        
Loss from continuing operations (in dollars per share) $ (0.33) $ (2.14) $ (2.56) $ (6.34)
Loss from discontinued operations (in dollars per share) (0.02)
Net loss per basic and diluted share (in dollars per share) $ (0.33) $ (2.14) $ (2.58) $ (6.34)
Weighted-average number of common shares outstanding - basic and diluted (in shares) 5,807,877 701,808 3,507,338 701,808